Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
home:diseases:ibd [02.17.2019]
sallieq [Inflammatory bowel disease (Crohn's disease and ulcerative colitis)]
home:diseases:ibd [03.13.2019] (current)
sallieq [Research]
Line 181: Line 181:
  
 ===== Research ===== ===== Research =====
 +
 +Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. ​ (({{pubmed>​long:​25023670}}))
 +
 +In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity. ​  ​(({{pubmed>​long:​25947920}}))
  
 Development,​ validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium. ​ (({{pubmed>​long:​25557335}})) ​ Development,​ validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium. ​ (({{pubmed>​long:​25557335}})) ​
home/diseases/ibd.txt · Last modified: 03.13.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.